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CD40L (CD154) on CD4+ T cells has been shown to
license dendritic cells (DCs) via CD40 to prime cyto-
toxic T lymphocyte (CTL) responses. We found that
the converse (CD40L on DCs) was also important.
Anti-CD40L treatment decreased endogenous CTL
responses to both ovalbumin and influenza infection
even in the absence of CD4+ T cells. DCs expressed
CD40L upon stimulation with agonists to Toll-like
receptor 3 (TLR3) and TLR9. Moreover, influenza
infection, which stimulates CTLs without help, upre-
gulated CD40L on DCs, but herpes simplex infection,
which elicits CTLs through help, did not. CD40L-defi-
cient (Cd40lg/) DCs are suboptimal both in vivo in
bone marrow chimera experiments and in vitro in
mixed lymphocyte reactions. In contrast, Cd40lg/
CD8+ T cells killed as effectively as wild-type cells.
Thus, CD40L upregulation on DCs promoted optimal
priming of CD8+ T cells without CD4+ T cells,
providing a mechanism by which pathogens may
elicit helper-independent CTL immunity.
INTRODUCTION
CD40L is a member of the tumor necrosis factor (TNF) super-
family whose expression is tightly regulated (Armitage et al.,
1992; Cayabyab et al., 1994; Grewal et al., 1996). Surface
expression on CD4+ T cells is detectable within 2 hr of activation
by peptide-pulsed antigen-presenting cells (APCs), peaks at 6 hr
and drops by 24 hr (Lee et al., 2002). Activated CD4+ T cells are
the predominant CD40L-bearing population. Modest expression
can be found on activated CD8+ T cells, B cells, NK cells, mono-
cytes, Langerhans cells, human thrombocytes, and activated
dendritic cells (DCs) (Pinchuk et al., 1996; Salgado et al., 1999;
Schonbeck and Libby, 2001). However, low or absent surface
staining for CD40L could be misleading for several reasons. First,
like FasL, much of the CD40L is stored in secretory lysosomes
and is only released to the cell surface upon activation (Koguchi
et al., 2007). Second, surface CD40L is rapidly endocytosed
upon binding to CD40 expressed on cells such as B cells and218 Immunity 30, 218–227, February 20, 2009 ª2009 Elsevier Inc.DCs, and third, detection of CD40L can be masked by soluble
CD40 (van Kooten et al., 1994; Yellin et al., 1994). CD40L on
CD4+ T cells is critical in effecting isotype switching by B cells
(Gray et al., 1994), ‘‘licensing’’ DCs to prime CTLs (Bennett
et al., 1998; Ridge et al., 1998; Schoenberger et al., 1998; Smith
et al., 2004) and generating memory CTLs (Borrow et al., 1996;
Sun and Bevan, 2003). Despite the vast literature on the function
of CD40L on CD4+ T cells (and hence CD40 on DCs and B cells),
less attention has been devoted to CD40L on the other cells that
express it, perhaps because of the modest expression.
Although CD4+ T cell help is important, helper-independent
primary CTL responses are generated against certain infections,
including viral infections with ectromelia, vesicular stomatitis
virus, human immunodeficiency virus, Epstein-Barr virus, influ-
enza, and cytomegalovirus (Andreasen et al., 2000; Buller
et al., 1987; Ruedl et al., 1999; Tripp et al., 1995; Zimmerli
et al., 2005). Likewise, helper-independent CTLs can be
generated against Listeria (Hamilton et al., 2001). The ascribed
mechanism by which helper-independent CTLs were elicited
was activation of DCs by the microbial infection (Ruedl et al.,
1999; Sun and Bevan, 2004) or self help by CD8+ T cells
(Hamilton et al., 2001; Wang et al., 2001), although the latter
mechanism fails to explain how such cells were stimulated to
begin with. Although many microbial pathogens directly activate
DCs, the basis of why only some pathogens can elicit helper-
independent CTLs remains unclear.
The use of a blocking CD40L mAb is also of translational
interest. The mAb can prolong graft survival dramatically in
both mouse and primate transplantation studies (Bucher et al.,
2005; Kirk et al., 1999). It can promote nonmyeloablative condi-
tioning for the establishment of chimerism (Ito et al., 2006) and it
can ameliorate autoimmunity (Bagenstose et al., 2005; Hanninen
et al., 2002; Komura et al., 2007). Most such studies have
presumed that the anti-CD40L acts on CD4+ T cells alone. We
have previously shown that in the absence of CD4+ T cells, treat-
ment with CD40L Ab still reduced CTL response to alloantigens
(Zhan et al., 2000). Another report has also shown that in the
absence of CD4+ T cells CD40L is still important for the priming
of transgenic CD8+ T cells (Hernandez et al., 2007) and
suggested a role for CD40L on CD8+ T cells.
No previous studies have explored the converse phenomenon
in which CD40L on DCs may trigger CD40 on T cells. We found
that endogenous in vivo CTL responses to cell-associated
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absence of CD4+ T cell help. We then set out to understand
the mechanism of anti-CD40L treatment and to determine the
role of CD40L in the absence of CD4+ T cells, including its
expression on CD8+ T cells and DCs. Results from both in vitro
mixed lymphocyte reactions and in vivo mixed bone marrow
(BM) chimera experiments directed us to focus on the role of
CD40L being expressed on DCs and the correlation between
CD40L upregulation by selected TLR agonists and viruses. We
found that TLR3 and TLR9 agonists and influenza could upregu-
late CD40L expression on DCs and that this was critical in effect-
ing helper-independent CTL responses. It should also be noted
that our studies primarily relate to primary CTL induction; the
parameters for the generation of memory may be different.
RESULTS
Anti-CD40L Treatment Decreases the Endogenous
In Vivo CTL Response
We initially used the endogenous CTL response to OVA as our
model system. Anti-CD40L treatment was administered intra-
peritoneally on the day of immunization with cell-associated
OVA (namely, OVA-coated spleen cells). Seven days later, we
assessed in vivo CTL activity by comparing the numbers of
peptide-loaded targets versus nonloaded targets. As expected,
we found that anti-CD40L or anti-CD4 treatment decreased the
endogenous CTL response (Figure 1A). Moreover, in the
absence of CD4+ T cells, CD40 antibody could substitute for
help and restore CTL killing (Figure 1A) as had been shown previ-
ously (Bennett et al., 1998; Schoenberger et al., 1998). The
agonistic anti-CD40 (FGK45) is thought to simulate CD4+ T cell
help to license DCs for CTL priming.
Initially, we thought that anti-CD40L acted by interfering with
CD4+ T cell licensing of DCs and thus had assumed that anti-
CD40L would have no effect in any model that induced CTLs
without CD4+ T cells. To investigate this, we used two different
mouse models that lack CD4+ T cells. In the first model, we
used GK mice, which secrete CD4 (GK1.5) antibody transgeni-
cally, effectively depleting the mouse of all peripheral CD4+
T cells (Zhan et al., 2004). In the second model, we analyzed
MHC class II-deficient mice, which are unable to positively
select for CD4+ T cells (Cosgrove et al., 1991). Again, we
used anti-CD40 to facilitate priming of CTL responses to
OVA-coated spleen cells. In both models, our results showed
that even in the absence of CD4+ T cells, the anti-CD40L Ab
treatment was still able to suppress the CTL response (Figures
1B and 1C). This indicated that the antibody treatment played
another role, apart from blocking CD4+ T cell help, and led
us to investigate what other cell type is being targeted by this
treatment.
CD40L Is Expressed on DCs
The expression of CD40L on CD4+ T cells has been well docu-
mented (Grewal et al., 1996). However, the expression of
CD40L on other cells has been less well characterized. CD40L
expression on DCs has been reported for human blood DCs
(Pinchuk et al., 1996), mouse Langerhans cells (Salgado et al.,
1999), mouse lung DCs (Masten et al., 1997), and plasmacytoid
DCs (Kuwajima et al., 2006). In preliminary studies, we found thatsurface staining of CD40L on splenic CD8+ T cells and DCs (both
resting and activated) was unconvincing. To further explore
CD40L expression, we next used intracellular staining because
we surmised that accumulation of CD40L after the addition of
monensin during the procedure might avail easier detection.
Lymph node cells obtained from naive wild-type C57BL/6 (B6)
or CD40L-deficient (Cd40lg/) mice were cultured for 4 hr in the
presence of PMA and ionomycin, permeabilized, and stained for
intracellular stores of CD40L. DCs were cultured overnight in
media, which is known to induce activation (Wilson et al.,
Figure 1. Treatment with Anti-CD40L Decreases the CTL Response
Even in the Absence of CD4+ T Cells
(A) Wild-type, (B) GK transgenicmiceand (C) MHC class II-deficient (H-2Ab1/)
mice were immunized with 23 107 irradiated OVA-coated spleen cells with 1 mg
LPS I.V. On the same day as immunization, 400 mg of anti-CD40L (MR1) or
control hamster IgG i.p. was administered. After 7–8 days, mice were given
i.v. 23 107 CFSEhi-labeled peptide-pulsed cells and CFSElo-labeled control
unpulsed cells in equal numbers. After 24 hr, spleens were analyzed by flow cy-
tometry. The percentage lysis was calculated by the reduction in the CFSEhi-
labeled peptide-pulsed target cells compared with unprimed mice. Each dot
represents a mouse and the bar represents the mean. CD4-deficient mice
(B and C) were treated with 100 mg of anti-CD40 (FGK45) i.p. on the day of
immunization. **p = 0.0076 and 0.0072, respectively, Mann-Whitney U Test.Immunity 30, 218–227, February 20, 2009 ª2009 Elsevier Inc. 219
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(Figure 2A), compared with either Cd40lg/ controls
(Figure 2A) or with control antibody staining (data not shown).
CD8+ T cells showed virtually no staining of CD40L (Figure 2B).
We found that CD40L was also expressed quite strongly on
cultured splenic DCs (Figure 2C). Given that CD40 is also found
on activated wild-type CD8+ T cells (Bourgeois et al., 2002; Sun
and Bevan, 2004; Figure 2D) and DCs, it was feasible that CD40L
expressed by DCs may interact with CD40 on T cells, in addition
Figure 2. CD40L Is Expressed on DCs and CD8+ T Cells Modestly
Express CD40
Lymph node cells from naive C57BL/6 (black line) or Cd40lg/ mice (gray,
filled) were stimulated in vitro for 4 hr with PMA and ionomycin. Cells were
stained for CD4 and CD8 and intracellular CD40L. The histogram in (A) is gated
on CD4+ cells and the one in (B) gated on CD8+ cells. As shown in (C), DCs
were purified from spleens of naive C57BL/6 (black line) or Cd40lg/ mice
(gray, filled) and cultured overnight prior to intracellular staining. All of the
above experiments were independently performed at least three times.
As shown in (D), lymph node cells from C57BL/6 mice were analyzed immedi-
ately or were activated with PMA and ionomycin. They were then stained with
CD8 and CD40 and analyzed with flow cytometry. Two independent experi-
ments were performed.220 Immunity 30, 218–227, February 20, 2009 ª2009 Elsevier Inc.to the previously described interaction of CD40L on T cells
interact with CD40 on DCs.
Cd40lg/ APCs Have Reduced Function in Priming
CD8+ T Cells
To explore further the role of CD40L being expressed by APCs,
we tested whether this CD40L was required for priming CD8+ T
cells in an endogenous CTL assay. To discriminate between
the role of CD40L on APCs and that of CD8+ T cells, we
generated mixed BM chimeras that would allow us to examine
independently the different cell types expressing CD40L. Irradi-
ated mice were reconstituted with equal parts of bm1 and
Cd40lg/ BM. Bm1 mice differ from B6 mice in that H-2Kbm1
has three mutations in the H-2Kb molecule that disallows
presentation of the OVA peptide SIINFEKL (Nikolic-Zugic and
Carbone, 1990). The resultant mice will have two sets of APCs.
One set can present OVA but is CD40L-deficient. The other set
cannot present SIINFEKL but is capable of expressing CD40L.
In this situation, any CTL priming must be due to the CD40L-defi-
cient APCs. For examination of CTL priming in the absence of
CD4+ T cell help, reconstituted mice were CD4-depleted and
treated with agonistic CD40 Ab. To exclude the possibility that
the bm1 T cells are unable to kill, we generated mixed chimeras
of bm1 and Rag1/ BM (1:1 ratio). Such mice will have bm1 T
cells and a set of wild-type B6 APCs (that can present OVA
and express CD40L). Our results (Figure 3A) showed that there
was a significant decrease in killing in bm1 Cd40lg/ chimeric
mice compared with the chimeric bm1 Rag1/ controls. Thus,
the Cd40lg/ APCs are less capable of eliciting CTL priming.
CD40L on DCs and CD40 on CD8 TCells Were Important
for CTL Induction
To show that DCs were critical in this CD40L-dependent antigen
presentation, we generated chimeric mice with CD11cDTR
(Probst et al., 2005) and Cd40lg/ BM. The CD11cDTR mice
express a fusion protein of the grivet monkey diphtheria toxin
receptor and green fluorescent protein (GFP) under the control
of the CD11c promoter. Therefore, all mice are generated simi-
larly and the reconstitution of DCs with Cd40lg/ versus
CD11cDTR Cd40lg+/+ genotype can easily be tracked by GFP
and CD11c expression (CD11c+GFP versus CD11c+GFP+).
Diphtheria toxin (DT) was administered to one group (100 ng
per 20 g mouse on day 1, 0, and 1 relative to immunization;
n = 5) and compared to untreated mice. All mice were depleted
of CD4+ T cells with 0.5 mg GK1.5 prior to immunizing with
23 107 irradiated OVA-coated spleen cells i.v. and 0.1 mg
anti-CD40 (FGK45) i.p. After 7 days, 23 107 CFSEhi-labeled
peptide pulsed cells and CFSElo-labeled control cells in equal
numbers were injected i.v. Spleens were analyzed 24 hr later in
this in vivo CTL assay. As shown in Figure 3B, the DCs in these
mixed BM chimeras comprise 32%–40% CD11cDTR and
60%–68% Cd40lg/. Thus the majority of DCs were of the
Cd40lg/ genotype, and therefore there was a bias to show
presentation function by the Cd40lg/ DCs. The depletion of
GFP+ CD11cDTR DCs (Cd40lg+/+ genotype) upon administration
of DT (Figure 3B) resulted in a substantial reduction (>50%) in
CTL killing (Figure 3C; p = 0.021). This confirms that DCs
expressing CD40L is a critical component of CTL priming in
the absence of CD4+ T cells.
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Independent CD8+ T Cells
(A, D, and E) Either (A) bm1 reconstituted or (D and E) Rag1/ reconstituted
mice were treated with 0.5 mg GK1.5 prior to immunizing with 23 107 irradi-
ated OVA-coated spleen cells with 1 mg LPS i.v. and 0.1 mg anti-CD40
(FGK45). Staining with a noncompeting RM4-4 Ab had shown that the CD4
depletion was complete. After 7–8 days, 23 107 CFSEhi-labeled peptide-
pulsed cells and CFSElo-labeled control unpulsed cells in equal numbers. After
24 hr, spleens analyzed by flow cytometry. The percentage lysis is calculated
by the reduction in the CFSEhi-labeled peptide-pulsed target cells compared
with unprimed mice. Error bars represent mean ± SEM. ***p = < 0.0002,
Mann-Whitney U Test.
(B and C) Elimination of Cd40lg+/+ DCs by diphtheria toxin (DT) in Cd40lg/
and CD11cDTR mixed BM chimeras. Chimeric mice were generated withTo show that Cd40/ but not Cd40lg/ CD8+ T cells have
reduced in vivo killing, we sublethally irradiated Rag1/ mice
(300 cGy) and reconstituted them with either Cd40lg/
(Figure 3D) or Cd40/ (Figure 3E) BM. Mice were depleted of
CD4+ T cells prior to immunizing with OVA-coated spleen cells
and CD40 Ab. Using CFSE-labeled peptide-coated cells to
detect differential in vivo lysis, we showed that Cd40lg/
CD8+ T cells but not Cd40/ CD8+ T cells could be primed to
become CTLs (Figures 3D and 3E).
Cd40lg/ DCs Are Inefficient at T Cell Priming, but
Cd40lg/ T Cells Are Able to be Stimulated In Vitro
To further test the role of CD40L expression by DCs on T cell
priming, we investigated an in vitro system, namely mixed
lymphocyte reactions (MLRs) between BALB/c and B6 cells,
by using naive CD8+ T cells as responders. Purified (97%–99%
purity) CD11c+ cells were used as APCs and the proliferation
of mismatched purified CD8+ T cells was measured by thymidine
incorporation after 3 days. The addition of anti-CD40L to the
MLR caused a significant decrease in proliferation of CD8+ T
cells (Figure 4A), supporting our earlier findings of its effect on
CTL generation in vivo. Whereas Cd40lg/ CD8+ T cells
behaved like wild-type CD8+ T cells (Figure 4B), Cd40lg/
DCs were poor stimulators compared to wild-type DCs (Fig-
ure 4C). Reciprocally, Cd40/ CD8+ T cells showed decreased
proliferation, consistent with a role of CD40L on DCs (Figure 4D).
Hence, for CD8+ T cell responders in MLR, it is important for DCs
to have CD40L and for CD8+ T cell responders to have CD40.
CD40L onDCs Is Upregulated uponActivationwith TLR3
and TLR9 Agonists
Our results above indicated that CD40L on DCs was important in
priming anti-CD40 potentiated CTL responses. This led us to
investigate whether anti-CD40 might upregulate CD40L on
DCs. We cultured DCs for 8 hr with CD40 Ab. This shortened
time point was necessary because longer incubation of DCs
(e.g., overnight) resulted in their activation (Wilson et al., 2006)
and CD40L upregulation (Figure 2C). Indeed, we found that
CD40L on DCs was upregulated by CD40 Ab (Figure 5A).
This raised the question whether other DCs-activating agents
like TLR agonists (mimicking infection) could also upregulate
CD40L on DCs. To test this, we used a panel of TLR agonists,
including pam2cys (TLR2), poly I:C (TLR3), LPS (TLR4), Loxori-
bine (TLR7), and CpG (TLR9). We observed expression of
CD40L when adding TLR3 agonists (poly I:C) or TLR9 agonists
for an 8 hr time point (Figure 5B). In contrast, agonists against
CD11cDTR BM and Cd40lg/ BM. DT was administered to one group
(n = 5) prior to immunization and compared to untreated mice (n = 5).
(B) Enumeration of DC reconstitution in chimeric mice. DCs were enriched with
a nycodenz gradient and stained for CD11c. DCs from CD11cDTR mice
express GFP. The top panel shows that the DCs comprise 35% CD11cDTR
and 65% Cd40lg/, and the bottom panel shows the reduced GFP expres-
sion (i.e., the GFP+ CD11cDTR DCs are depleted) after DT administration.
(C) Mice were treated with 0.5 mg GK1.5 prior to immunizing with 23 107 irra-
diated OVA-coated spleen cells I.V. and 0.1 mg anti-CD40 (FGK45). After
7 days, 23 107 CFSEhi-labeled peptide-pulsed cells and CFSElo-labeled
control cells in equal numbers were injected i.v. Spleens were analyzed
24 hr later. Percentage lysis was calculated by the reduction in the peptide-
pulsed target cells compared to unprimed mice.Immunity 30, 218–227, February 20, 2009 ª2009 Elsevier Inc. 221
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activating DCs as shown by CD86 expression (Figure S1 avail-
able online), did not upregulate CD40L (Figure 5B).
The Potentiation of Helper-Independent CTL Responses
by TLR3 and TLR9 Agonists Is Dependent on CD40L
Upregulation
As shown above, anti-CD40 can upregulate CD40L on DCs and
facilitate CTL priming in the absence of CD4+ T cells. Because
TLR3 and TLR9 agonists could also upregulate CD40L on
DCs just like anti-CD40 (Figure 5B), we wanted to determine
whether these agonists could also potentiate helper-indepen-
dent CTL responses. We showed that in CD4 T cell-deficient
mice (GK mice), the only TLR ligands to allow helper-indepen-
dent CTL induction were those that upregulated CD40L, namely
poly I:C and CpG (black columns; Figure 5C). Moreover, this
induction was dependent on CD40L, given that anti-CD40L
dramatically reduced the CTL response (white columns;
Figure 5C).
Helper-Independent Pathogens May License APCs
by Upregulating CD40L
Because agonists to TLR3 and TLR9 can activate APC to poten-
tiate helper-independent CTL responses, we investigated
whether a pathogen itself is able to have the same function. It
has been known that some pathogens are able to elicit immune
responses in the absence of CD4+ T cells (Behrens et al., 2004;
Shedlock and Shen, 2003; Sun and Bevan, 2003) and that this
was due to such viruses activating DCs (Wu and Liu, 1994).
However, no differential activation between viruses that elicit
CTLs without help and those that do not has been forthcoming.
Figure 4. Cd40lg/ DCs Are Inefficient at
Eliciting MLR
A total of 23 105 purified CD8+ T cells were
cultured with allogeneic purified CD11c+ DCs for
3 days prior to the addition of [H3] thymidine.
Proliferation was measured by the incorporation
of [H3] thymidine above that of syngeneic cultures.
(A) shows MLR using B6 T cells with BALB/c DCs
or BALB/c T cells with B6 DCs in the presence of
anti-CD40L or control hamster IgG. (B) shows
Cd40lg/ compared with wild-type B6 T cells
reacting to BALB/c DCs. (C) shows Cd40lg/
compared with wild-type B6 DCs as presenters
to BALB/c T cells. (D) shows Cd40/ compared
with wild-type B6 T cells reacting to BALB/c
DCs. **p < 0.005, Mann Whitney U Test. Mean +
SEM are shown.
Thus, we questioned whether the upre-
gulation of CD40L is required for these
helper-independent responses. To inves-
tigate this, we chose two viruses: influ-
enza whose primary effector CTL
responses are mainly helper independent
(Allan et al., 1990; Tripp et al., 1995) and
herpes simplex virus (HSV) whose CTL
responses are mainly helper dependent
(for the intravenous and intradermal route
[Smith et al., 2004]; for flank infection, Figure S2).
Mice depleted of CD4+ T cells were infected intranasally with
influenza virus and treated with either anti-CD40L or control
IgG. The CTL response against the influenza NP peptide-pulsed
cells was reduced in the treated mice (Figures 6A and 6B). The
number of NP-specific CD8+ T cells was also dramatically
reduced as shown with tetramer staining (Figure 6C). Thus, we
hypothesized that part of helper independence for influenza-
induced CTL immunity is the virus’s ability to upregulate
CD40L on APC. Indeed, we showed that influenza infection of
DCs upregulated CD40L expression in vitro, whereas HSV did
not (Figure 6D), even though both viruses upregulated CD86
(Figure 6D). Therefore, we conclude that upregulation of
CD40L on APCs is one mechanism by which some pathogens
are able to elicit helper-independent effector CTLs.
DISCUSSION
CD40-CD40L interactions have long been associated with DC
maturation (O’Sullivan and Thomas, 2003), although the majority
of investigations have approached this from the angle of DCs
displaying CD40. Because both CD40L and CD40 are found in
CD4+ T cells, DCs (highlighted in this study), and CD8+ T cells,
there are many potential permutations for amplifying the
response within or between each cell type. Moreover such
potential interactions may differ among various situations, e.g.,
between initial CTL induction and memory generation. In this
study, we have provided evidence that CD40L is required on DCs
for optimal priming of naive CD8+ T cells to become CTLs. Our
results showed that anti-CD40L treatment decreased the endog-
enous in vivo cytotoxic T cell response to OVA. Anti-CD40L222 Immunity 30, 218–227, February 20, 2009 ª2009 Elsevier Inc.
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CD40L on DCs Promotes Helper-Independent CTLsFigure 5. CD40L Is Upregulated in DCs by TLR3 and TLR9 Agonists
and These Agonists Can Potentiate CD40L-Dependent CTL
Responses
DCs were purified (CD11c+) and cultured for 8 hr with (A) CD40 monoclonal
antibody (FGK45) or (B) a panel of agonists for TLR2, TLR3, TLR4, TLR7,
and TLR9. Histograms show expression of intracellular CD40L on gated
CD11c+ cells from C57BL/6 mice (black line) relative to Cd40lg/ mice
(gray filled). As shown in (C), GK (CD4-deficient) mice were immunized with
23 107 irradiated OVA-coated spleen cells with 1 mg LPS i.v. and 0.1 mg
anti-CD40, 40 nmols CpG, 20 nmols Pam2Cys, 1 mg Loxoribine, or 100 mg
Poly I:C. Anti-CD40L or hamster IgG, 400 mg, was also given on the day of
immunization. After 7 days, 23 107 CFSEhi-labeled peptide-pulsed cells and
CFSElow-labeled control unpulsed cells in equal numbers were injected i.v.
After 24 hr, spleens were analyzed by flow cytometry. The percentage lysis
was calculated by the reduction in the CFSEhi-labeled peptide-pulsed targettreatment was most effective when used on the day of immuni-
zation, which inferred interference at the priming or expansion
phase rather than the effector phase. Although the importance
of CD40L expression by CD4+ T cells and CD40 by DCs in
licensing DCs for CTL priming is not in dispute, little attention
has been drawn to the possible role for CD40L expression by
DCs in helper-independent responses. In using two different
models of CD4-deficient mice, we have shown that anti-CD40L
treatment decreased the CTL response in the absence of
CD4+ T cells. Thus, in the absence of CD4+ T cells, anti-CD40L
treatment must be targeting another cell type that expresses
CD40L. Upon examination of CD40L expression on various cell
types, we discovered that CD40L was upregulated on DCs.
This CD40L seemed to be functionally required because in vivo
CTL assays in BM chimeras showed that when the DCs are
Cd40lg/, killing was reduced. Likewise in vitro, MLRs show
that Cd40lg/ DCs did not prime T cells as effectively as wild-
type DCs, whereas Cd40lg/ CD8+ T cells proliferated just as
efficiently as wild-type CD8+ T cells. Cd40/ CD8+ T cells
however, in both in vivo and in vitro assays, were less efficacious
than wild-type or Cd40lg/ CD8+ T cells. CD40 expression by
T cells, especially activated ones, has been reported previously
(Bourgeois et al., 2002; Munroe and Bishop, 2007), although the
role for CD40 on CD8+ T cells remained undefined. It has been
shown to have a costimulatory function, augmenting in vitro
responses to agonists against CD3 and CD28 (Munroe and
Bishop, 2007). Our work may give insight into an undefined
pathway in which the CD40 on these CD8+ T cells interact with
the CD40L on the DCs. Our hypothesis that CD40L on DCs is
important in helper-independent responses does not discredit
the notion that CD40 may also play a role in some situations.
Hernandez et al., (2007) had ascribed a role of CD40L on
CD8+ T cells; much of that work used the P-14 TCR transgenic
system (and lymphocytic choriomeningitis virus gp33 peptide
on H-2Db). In contrast, we have found no evidence that CD40L
is important on CD8+ T cells in our endogenous models given
that Cd40lg/ CD8+ T cells were able to have normal cytotoxic
activity in the presence of Cd40lg+ DCs. We have also looked at
TCR-transgenic models; namely, OT-I and found OT-I T cells
were not reliant on CD40L for proliferation or killing (data not
shown). Given the recent findings that clonal size is important
in determining outcomes, it may not be surprising that there
may be differences between TCR-transgenic systems and
endogenous systems (Ford et al., 2007; Mintern et al., 2002).
One of the key components of the Hernandez paper was that
the Cd40lg/ P-14 T cells proliferated poorly compared with
wild-type P-14 T cells in vivo. Interestingly, anti-CD40 stimula-
tion availed these Cd40lg/ T cells to proliferate, and this
suggests that CD8+ T cells do not require CD40L to proliferate.
Our proposal that CD40 Ab can upregulate CD40L on DCs to
prime CD8+ T cells would explain this result.
We therefore propose that CD40L on the DCs interacts with
the CD40 on CD8+ T cells and is crucial for helper-independent
CTL responses. Given that CD40 is expressed on other immune
cells including CD4+ T cells, B cells, endothelial cells, thymic
epithelial cells and DCs themselves (Gray et al., 2006; Quezada
cells compared with unprimed mice. The graph shows mean + SD; n = 3.
Two independent experiments were performed.Immunity 30, 218–227, February 20, 2009 ª2009 Elsevier Inc. 223
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on the Dendritic Cell and Generate CD40L
Partially Dependent CTLs
Mice treated with GK1.5 (anti-CD4) were infected
with 30 pfu intranasal influenza (PR8 strain); on
the same day, 400 mg anti-CD40L or IgG treatment
was administered. Six days later, mice were
injected with 23 107 CFSEhi-labeled peptide
(influenza NP366-374)-pulsed cells and CFSE
lo-
labeled control unpulsed cells. After 24 hr, spleens
were analyzed by flow cytometry. In (A), histo-
grams showed the two peaks indicating CFSEhi
peptide-pulsed cells versus CFSElo unpulsed cells
in hamster IgG-treated and anti-CD40L-treated
mice. As shown in (B), the percentage lysis was
calculated by the reduction in the peptide-pulsed
target cells compared with uninfected mice. The
graph shows mean and SEM. **p = 0.0027,
Mann-Whitney U Test. As shown in (C), medias-
tinal lymph nodes were taken from CD4-depleted
influenza infected mice at day 5 and stained with
NP tetramer. The bar graph shows the total number of CD8+ NP-specific T cells. The graph shows mean ± SEM. *p = 0.0286, Mann-Whitney U test. As shown
in (D), CD11c+ DCs were purified and infected for 1 hr with 5 pfu per cell of either PR8 influenza or HSV. DCs were then cultured for 6 hr prior to surface staining of
CD11c and CD86 and intracellular staining of CD40L. Histograms are gated on CD11c+ cells. CD40L histograms show B6 (black line) overlaid onto Cd40lg/
DCs (gray filled). CD86 histograms show HSV- or influenza-infected (black line) cells overlaid onto uninfected DCs (gray filled). All experiments were performed at
least twice.et al., 2004; van Kooten and Banchereau, 2000), whether CD40L
on DCs may interact with CD40 of all these cell types invites
further elucidation. The CD40L on DCs could be induced
in vitro upon activation with TLR3 and TLR9 agonists. TLR3
and TLR9 agonists could also be used to generate helper-
independent CTL responses; this could be dramatically blocked
by anti-CD40L. However agonists to TLR2, TLR4, and TLR7
failed to upregulate CD40L and were unable to deliver signals
to prime T cells in vivo. Thus so that helper-independent CTL
responses could be generated, TLR3 and TLR9 agonists can
upregulate CD40L expression on DCs and promote CTL priming.
TLR3 and TLR9 agonists (but not TLR2 or TLR4 agonists) have
previously been shown to facilitate crosspresentation in vitro
(Datta et al., 2003). Moreover, the addition of TLR3 or TLR9
agonists to cationic liposomes can elicit in vivo crosspriming of
CD8+ T cells independent of CD4+ T cell help (Zaks et al.,
2006). Our findings now offer a mechanistic explanation for their
findings, i.e., upregulation of CD40L on DCs by agonists to TLR3
and TLR9 promotes CD8+ T cell priming.
Because TLR agonists mimic microbial infection, we surmised
that pathogens that promote CTL priming in a helper-indepen-
dent fashion may do so by upregulating CD40L on DCs. Viruses
can infect both human and murine DCs, leading to activation and
upregulation of costimulatory molecules such as CD40 and
CD80-CD86 (Harui et al., 2006; Jain et al., 2007; Montoya
et al., 2005; Saurwein-Teissl et al., 1998; Wu and Liu, 1994).
CD40L as a costimulatory marker on DCs has not been investi-
gated in this capacity, presumably because most workers
assume that CD40L is primarily a T cell molecule. We chose
two infectious models: intranasal influenza, which is helper inde-
pendent (Allan et al., 1990; Tripp et al., 1995) and HSV flank
infection, which is mostly dependent on CD4 help, just like for
the intravenous or footpad route (Smith et al., 2004). CD40L on
DCs was upregulated by influenza but not by HSV, whereas
both infections upregulated CD86 on DCs. Moreover, the224 Immunity 30, 218–227, February 20, 2009 ª2009 Elsevier Inc.helper-independent CTL responses by influenza were substan-
tially reduced by anti-CD40L treatment.
The mechanism of how viruses like ectromelia, vesicular
stomatitis virus, human immunodeficiency virus, Epstein-Barr
virus, influenza, and cytomegalovirus can potentiate helper-inde-
pendent CTL responses in the absence of CD4 help remained
unclear despite much exploration (Hamilton et al., 2001; Ruedl
et al., 1999; Sun and Bevan, 2004; Wang et al., 2001). Our work
provides at least one mechanism by which some viruses can elicit
CTL responses in a CD4-deficient environment. Many viruses,
such as HIV (Lore et al., 2002; Trimble et al., 2000), MCMV
(Mintern et al., 2006), HPV (Ortiz-Sanchez et al., 2007), HCMV
(Moutaftsi et al., 2002), and HSV (Mikloska et al., 2001), have
developed evasion strategies that downregulate costimulatory
markers on both T cells and DCs. This evasion mechanism leads
to decreased T cell-mediated immunity to the virus, thereby
allowing chronic infections to manifest. Interestingly, HIV has
been shown to downregulate CD40L on T cells (Subauste et al.,
2007), thus it would be interesting to speculate that CD40L on
DCs may also be downregulated. Correcting such a deficiency
(e.g., by TLR agonists) could potentially lead to increased immu-
nity in the absence of CD4+ T cells in HIV+ patients. There is
ongoing work investigating the creation of viruses or cell lines
expressing CD40L (Bereta et al., 2004; Dotti et al., 2001; Mehling
et al., 2001; Ostrowski et al., 2000; Tomihara et al., 2008) for either
vaccine strategies or eradication of tumors with cell-based
therapies. Our findings that CD40L upregulation on DCs is
involved in generating CTL responses to influenza virus may
lead to increased understanding of how these therapies may be
tailored.
In conclusion, we show that CD40L upregulation on DCs allows
the generation of helper-independent CTLs. This CD40L upregu-
lation also explains why only certain TLR agonists can promote
helper-independent CTLs and provides a mechanism by which
certain viruses can stimulate helper-independent CTLs.
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Mice
Mice aged 6 to 8 weeks were used in all experiments. CD4-deficient mice GK5
(transgenic for anti-CD4 monoclonal antibody [Zhan et al., 2004]), CD40L-defi-
cient mice (CD154-H) (Xu et al., 1994), MHC class II-deficient mice (Cosgrove
et al., 1991), CD11cDTR mice (Probst et al., 2005), Rag1/ (Mombaerts et al.,
1992) Cd40/, and MHC class I:C.H-2bm1 (called bm1) mice were maintained
in specific pathogen-free conditions in the animal facilities of Walter and Eliza
Hall Institute of Medical Research. All mice were used according to the regu-
lations of the Institute Animal Ethics Committee.
DCs Preparations
DCs were harvested from spleens as previously described (Vremec et al.,
1992). Spleens were finely diced and added to a collagenase-DNase solution.
Digestion occurred for 25 min before EDTA was added. After sieving, diluting,
and centrifuging, the pellet was then resuspended in 5 mL of Nycodenz/4
spleens and overlaid onto an additional 5 mL Nycodenz in a polypropylene
tube. A total of 2 mL of FCS-EDTA was overlaid onto the splenic cell layer.
The gradient was then centrifuged at 4000 rpm without brake for 15 min.
The low-density cells were collected and washed with EDTA-BSS-FCS before
cell counts were performed. A depletion antibody cocktail containing anti-
bodies against CD3, Thy1, GR1, B220, and Ery was added to negatively select
for DCs. Dynabeads sheep anti-rat IgG magnetic beads (Dynal Biotech, Oslo,
Norway) were washed in EDTA-BSS-FCS and added at five beads per cell for
20 min at 4C on a slowly rotating mixer. Cells were then depleted via negative
selection on a magnet (Miltenyi Biotec, Bergisch Gladbach, Germany), and the
supernatant was collected and the depletion was performed twice for extra
purity. Cells were washed in EDTA-BSS-FCS, counted, and checked via
flow cytometry for yield.
Intracellular Staining
Cells were stained intracellularly for CD40L. T cells from B6 mice or Cd40lg/
mice were cultured 43 106 cells/ml in a 24-well plate in RPMI with 10% FCS in
5% incubator. For activation, cells were incubated with PMA (25 ng/ml) and
Ionomycin (1 mg/ml) for 3 hr. Monensin (Golgistop, Becton Dickinson, Franklin
Lakes, NJ, USA) at 0.6 ml/ml was added to the cultures so that transport out of
the cells was prevented. Cells were washed and stained with surface markers
prior to fixing. Cells were fixed with 100 ml Cytofix (Becton Dickinson) for
20 min at 4C. Cells were permeabilized in saponin (PermWash, Becton Dick-
inson) before staining with biotinylated CD40L and allophycocyanin-streptavi-
din (BDBiosciences, San Jose, CA, USA).
In Vivo CTL Assays
Mice were immunized with 23 107 irradiated OVA-coated spleen cells from
either a B6 or bm1 donor with 1 mg LPS i.v. Seven days later, mice were given
i.v. 23 107 CFSEhi-labeled SIINFEKL (Mimotopes, Clayton, Australia) peptide-
pulsed cells and CFSElo-labeled control unpulsed cells in equal ratios. Spleens
were analyzed by flow cytometry 18–24 hr later.
Generation of Chimeric Mice
Lethal irradiation consisted of two doses of 550 cGy (g-irradiation; 60Co
source) 2 hr apart. Femoral BM, 13 106 cells were injected i.v. into the recip-
ient mice within hours of irradiation. Neomycin sulfate was added prophylac-
tically to the drinking water for 4 weeks postirradiation. We treated mice with
100 ml of Thy1 antibody (T24) i.p. day 1 postreconstitution to eliminate residual
host T cells. Chimeric mice were used experimentally 6–8 weeks later.
Mixed Lymphocyte Reactions
Spleens and lymph nodes were isolated from C57BL/6, BALB/c, or Cd40lg/
mice. DCs and CD8+ T cells were purified by MACS (Miltenyi Biotech) positive
selection. A total of 23 105 T cells, as responders, were cultured with alloge-
neic DCs, as stimulators, at concentrations of 1:100. Cells were cultured in
a 96-well round-bottom plate in MT-RPMI-10% FCS with 55 mM 2-mer-
capto-ethanol and incubated with 5% CO2. Syngeneic stimulators and
responders were used as background controls. [H3] thymidine was added
2 or 3 days later. Cells were harvested 18 hr after the addition of [H3] thymidine,
and proliferation was measured as CPM over background.Antibodies and TLR Agonists
Anti-CD40L (MR1), anti-CD40 (FGK45), and anti-CD4 (GK1.5) were purified
by in-house facilities. Flow cytometry antibodies were purchased from
BDBiosciences. Loxoribine and polyinosinic-polycytidilyc acid (Poly I:C) were
purchased from Invivogen, San Diego, CA, USA; lipopolysaccharide (LPS)
from E. coli 0111:B4 was purchased from Sigma, St Louis, MO, USA. D. Jack-
son, University of Melbourne, generously provided Pam2Cys.
Viral Infections
All viruses were stored at 70C in PBS as single-use aliquots. The influenza
strain used was influenza A/Puerto Rico/8/34 (Mt Sinai, H1N1) (PR8). Titer of
the original influenza virus AF17B = 3.13 107 plaque forming units (pfu)/ml.
B6 mice were infected with 30 pfu per mouse of the above strain of influenza
intranasally in a volume of 20 ml. Purified DCs were infected by incubating at
37C for 45 min with virus at a concentration of 5 pfu/cell. The suspension
was swirled periodically. We washed DCs three times in KDS-RPMI-FCS to
ensure any excess virus was removed prior to incubation for 5 hr to upregulate
surface markers.
HSV flank infections were performed as previously described (Allan et al.,
2006; van Lint et al., 2004).
Tetramer Staining
Mediastinal lymph nodes were removed from mice infected with influenza
5 days prior. Cells were prepared into a single-cell solution and incubated
with NP tetramer-PE, 1 in 200, for 40 min at room temperature. Cells on ice
were stained for CD8 for 30 min and analyzed via flow cytometry.
Statistical Methods
Data are shown as mean ± SEM. Nonnormally distributed data were compared
with unpaired Mann-Whitney U Tests.
SUPPLEMENTAL DATA
Supplemental Data include two figures and can be found with this article online
at http://www.immunity.com/supplemental/S1074-7613(09)00067-3.
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